These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9304108)

  • 1. RSV-IGIV therapy: a cost/benefit analysis.
    Thakur BK; Wu LR; Schaeufele JF
    Pediatrics; 1997 Sep; 100(3 Pt 1):417-8. PubMed ID: 9304108
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.
    Pediatrics; 1997 Jan; 99(1):93-9. PubMed ID: 8989345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn.
    Pediatrics; 1997 Apr; 99(4):645-50. PubMed ID: 9093323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B; Müller W
    Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
    O'Shea TM; Sevick MA; Givner LB
    Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of local guidelines for prevention of respiratory syncytial viral infections.
    Hall CB; Stevens TP; Swantz RJ; Sinkin RA; McBride JT
    Pediatr Infect Dis J; 1999 Oct; 18(10):850-3. PubMed ID: 10530578
    [No Abstract]   [Full Text] [Related]  

  • 7. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure?
    Moler FW
    Pediatrics; 1999 Sep; 104(3 Pt 1):559-60. PubMed ID: 10469785
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Hemming VG
    Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of RSV-IVIG in premature infants: success in the home.
    Hayes C; Wilkerson S; Bibb K; Schuschke L; Guest A
    Pediatrics; 1999 Mar; 103(3):698-9. PubMed ID: 10189302
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antibody and use of respiratory syncytial virus (RSV) immune globulin to prevent severe RSV disease in high-risk children.
    Groothuis JR
    J Pediatr; 1994 May; 124(5 Pt 2):S28-32. PubMed ID: 8169755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
    Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.
    Simoes EA; Sondheimer HM; Top FH; Meissner HC; Welliver RC; Kramer AA; Groothuis JR
    J Pediatr; 1998 Oct; 133(4):492-9. PubMed ID: 9787686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
    Robinson RF; Nahata MC
    Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children.
    Simoes EA; Groothuis JR; Tristram DA; Allessi K; Lehr MV; Siber GR; Welliver RC
    J Pediatr; 1996 Aug; 129(2):214-9. PubMed ID: 8765618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Levin MJ; Hall CB; Long CE; Rodriguez WJ; Arrobio J; Meissner HC; Fulton DR; Welliver RC
    N Engl J Med; 1993 Nov; 329(21):1524-30. PubMed ID: 8413475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assault against respiratory syncytial virus: beginning of an era.
    Abzug MJ
    Lancet; 1997 Mar; 349(9054):743-4. PubMed ID: 9074568
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.